NCT07744256 — Small Cell Lung Cancer (SCLC) trial site landscape

Public-registry site landscape for NCT07744256, “Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)”, a Small Cell Lung Cancer (SCLC) study sponsored by Beijing Biotech. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07744256 (registry record)
Study title	Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Official title	A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer
Sponsor	Beijing Biotech
Condition(s)	Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC; Extensive-stage SCLC
Phase	PHASE1 / PHASE2
Listed sites	1
Site countries	China

Recruiting-density context

At Peking University Shenzhen Hospital — one of the facilities listed on this trial — 23 other studies are actively recruiting Small Cell Lung Cancer (SCLC) patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.

Patient-friendly overview of this study: eichor.com/study/NCT07744256.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07744256 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →